Article
Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial.
Lancet (London, England) - 6 Jun 2015
Mega Jessica L, Walker Joseph R, Ruff Christian T, Vandell Alexander G, Nordio Francesco, Deenadayalu Naveen, Murphy Sabina A, Lee James, Mercuri Michele F, Giugliano Robert P, Antman Elliott M, Braunwald Eugene, Sabatine Marc S
Abstract excerpt
BACKGROUND: Warfarin is the most widely used oral anticoagulant worldwide, but serious bleeding complications are common. We tested whether genetic variants can identify patients who are at increased risk of bleeding with warfarin and, consequently, those who would derive a greater safety benefit with a direct oral anticoagulant rather than warfarin. METHODS: ENGAGE AF-TIMI 48 was a randomised, double-blind trial...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.